Compare Amgen, Inc. (AMGN) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs General Motors Company — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while General Motors Company trades at $77.8 (market cap $70.19B). The key difference: Amgen, Inc. is far larger — about 2.8× General Motors Company's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GM | |
|---|---|---|
Market Cap | $196.12B | $70.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $86.38 |
52-Week Low | $271.18 | $48.89 |
Enterprise Value | $241.41B | $173.53B |
Dividend Yield | 2.77% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
General Motors (GM) trades at $77.85, up 1.57% with a bearish technical signal despite three consecutive quarterly earnings beats. The company maintains strong cash flow generation ($26.9B operating cash flow in 2025) and trades at discounted valuations (P/S 0.4, P/B 1.12). Recent news highlights GM's strategic pivot into energy and battery technology partnerships as automotive sales face industry headwinds.
GM presents a value opportunity with analyst consensus price target of $100.27 (29% upside) but faces execution risks in EV transition and margin pressure. The stock's outlook depends on Q2 earnings delivering clean cash flow and sustained margin improvement amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
